S
Sanjay Gurunathan
Researcher at Sanofi Pasteur
Publications - 46
Citations - 6764
Sanjay Gurunathan is an academic researcher from Sanofi Pasteur. The author has contributed to research in topics: Vaccination & HIV vaccine. The author has an hindex of 26, co-authored 40 publications receiving 5856 citations. Previous affiliations of Sanjay Gurunathan include Sanofi S.A..
Papers
More filters
Journal ArticleDOI
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm,Punnee Pitisuttithum,Sorachai Nitayaphan,Jaranit Kaewkungwal,Joseph Chiu,Robert Paris,Nakorn Premsri,Chawetsan Namwat,Mark de Souza,Elizabeth Adams,Michael Benenson,Sanjay Gurunathan,Jim Tartaglia,John G. McNeil,Donald P. Francis,Donald Stablein,Deborah L. Birx,Supamit Chunsuttiwat,Chirasak Khamboonruang,Prasert Thongcharoen,Merlin L. Robb,Nelson L. Michael,Prayura Kunasol,Jerome H. Kim +23 more
TL;DR: This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection in a community-based population with largely heterosexual risk and offer insight for future research.
Journal ArticleDOI
Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults
Abstr Act,Carlos A. DiazGranados,Andrew J. Dunning,Murray A Kimmel,John J. Treanor,Avi Collins,Richard Pollak,Janet Christoff,John Earl,Victoria Landolfi,Earl Martin,Sanjay Gurunathan,Richard P. Nathan,David P. Greenberg,Nadia Tornieporth,Michael D. Decker,H. Keipp Talbot +16 more
TL;DR: Among persons 65 years of age or older, IIV3-HD induced significantly higher antibody responses and provided better protection against laboratory-confirmed influenza illness than did IIV3-SD.
Journal ArticleDOI
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
Saranya Sridhar,Alex Luedtke,Edith Langevin,Ming Zhu,Matthew Bonaparte,Tifany Machabert,Stephen Savarino,Betzana Zambrano,Annick Moureau,Alena Khromava,Zoe Moodie,Ted Westling,Cesar Mascareñas,Carina Frago,Margarita Cortés,Danaya Chansinghakul,Fernando Noriega,Alain Bouckenooghe,Josh Chen,Su-Peing Ng,Peter B. Gilbert,Sanjay Gurunathan,Carlos A. DiazGranados +22 more
TL;DR: CYD‐TDV protected against severe VCD and hospitalization for VCD for 5 years in persons who had exposure to dengue before vaccination, and there was evidence of a higher risk of these outcomes in vaccinated people who had not been exposed to d Dengue.
Journal ArticleDOI
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination
Elisa Nemes,Hennie Geldenhuys,Virginie Rozot,Kathryn Tucker Rutkowski,Frances Ratangee,Nicole Bilek,Simbarashe Mabwe,Lebohang Makhethe,Mzwandile Erasmus,Asma Toefy,Humphrey Mulenga,Willem A. Hanekom,Steven G. Self,Linda-Gail Bekker,Ryall Robert P,Sanjay Gurunathan,Carlos A. DiazGranados,Peter Andersen,Ingrid Kromann,Thomas J. Evans,Ruth D. Ellis,Bernard Landry,David A. Hokey,Robert Hopkins,Ann M. Ginsberg,Thomas J. Scriba,Mark Hatherill +26 more
TL;DR: The rate of sustained QFT conversion, which may reflect sustained M. tuberculosis infection, was reduced by vaccination in a high‐transmission setting, and this finding may inform clinical development of new vaccine candidates.
Journal ArticleDOI
The promise of mRNA vaccines: a biotech and industrial perspective.
TL;DR: The state of the art for the prevention of infectious diseases by using mRNA and pertinent topics to the biotechnology and pharmaceutical industries is reviewed.